Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 Antibody + Bevacizumab + HAIC in Advanced HCC
NCT06742424Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective Response Rate at 24 months. Started Oct 2024; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06742424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742424.